Compile Data Set for Download or QSAR
Report error Found 204 Enz. Inhib. hit(s) with all data for entry = 10646
TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556772(US11352339, Example 15 | 3-(3-([1,1′-Bipheny...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556774(US11352339, Example 17)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556776(Trans-3-(3-([1,1′-biphenyl]-3-yl)-1H-pyrazol...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556816(US11352339, Example 55)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556838(US11352339, Example 76)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556876(US11352339, Example 111 | 3-(3-([1,1′-Biphen...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556879(Trans-3-(3-([1,1′-biphenyl]-3-yl)-1H-1,2,4-t...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556879(Trans-3-(3-([1,1′-biphenyl]-3-yl)-1H-1,2,4-t...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556882(US11352339, Example 117 | 3-(3-([1,1′-Biphen...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556883(US11352339, Example 118)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556884(US11352339, Example 119)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556910(US11352339, Example 145)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556922(US11352339, Example 157)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556926(US11352339, Example 161)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556928(US11352339, Example 163)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556931(US11352339, Example 166)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556939(US11352339, Example 174)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556940(US11352339, Example 175)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556946(US11352339, Example 181 | (S)-4-(3-(1-Cyanopyrroli...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556948(US11352339, Example 183 | (S)-6-(3-(1-Cyanopyrroli...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556949(US11352339, Example 184 | 2-(5-(2-(3-(Trifluoromet...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556951(US11352339, Example 186 | (S)-2-(5-(2-(3-Cyanophen...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556953(US11352339, Example 188 | (S)-4-(4-(3-(1-Cyanopyrr...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556957(US11352339, Example 192 | (S)-1-(6-(3-(1-Cyanopyrr...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556959(US11352339, Example 194 | 3-(5-(5-Phenylpyridin-2-...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556960(US11352339, Example 195 | 3-(3-(5-(Pyrimidin-2-yl)...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556965(US11352339, Example 200)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556968(US11352339, Example 203 | (S)-4-(6-(3-(1-Cyanopyrr...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556757(US11352339, Example 1)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556762(US11352339, Example 5)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556765(US11352339, Example 8)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556769(US11352339, Example 12)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556771(US11352339, Example 14 | 3-(3-([1,1′-Bipheny...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556773(US11352339, Example 16)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556775(US11352339, Example 18 | 3-(3-(Naphthalen-2-yl)-1H...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556776(Trans-3-(3-([1,1′-biphenyl]-3-yl)-1H-pyrazol...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556776(Trans-3-(3-([1,1′-biphenyl]-3-yl)-1H-pyrazol...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556778(US11352339, Example 23 | US11352339, Example 21)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556778(US11352339, Example 23 | US11352339, Example 21)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556781(US11352339, Example 24)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556782(US11352339, Example 25)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556783(US11352339, Example 26)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556785(US11352339, Example 28)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556786(US11352339, Example 29)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556787(US11352339, Example 30)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556790(US11352339, Example 33)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556792(US11352339, Example 35)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556793(US11352339, Example 36)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556794(US11352339, Example 39 | US11352339, Example 37)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM556795(US11352339, Example 40 | US11352339, Example 38)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 204 total ) | Next | Last >>
Jump to: